Effect of norgestomet treatment on plasminogen activator activity in the cervical mucus and the endometrium in dairy cows.
The aim of this study was to determine the effect of norgestomet treatment, in the absence or the presence of a functional corpus luteum (CL), on plasminogen activators activity (PAA) in the cervical mucus and the endometrium in dairy cows. Eleven days after oestrus (Day 0 = oestrus), 38 cows were randomly assigned to one untreated control group (n = 9) and three treatment groups (S(1), S(2) and S(3)). Animals of S(1) group (n = 9) received an implantation of norgestomet on the outer surface of the ear for 8 days, simultaneous injection of oestradiol valerate 5 mg and norgestomet 3 mg, i.m., and on Day 19 an injection of ECG 500 IU, i.m. Animals of S(2) group (n = 11) received the treatment of S(1) group, plus an administration of PGF(2)alpha on Day 10 for the regression of CL. Animals of S(3) group received the treatment of S(2) group, plus two additional norgestomet implants inserted on Day 16 for 36 h. Both types of plasminogen activators [the tissue-type (t-PA) and the urokinase-type (u-PA)] were detected in the cervical mucus and the endometrium of the cows. Plasminogen activators activity in the cervical mucus was higher in control group than in S(1), S(2) and S(3) groups (P < 0.001). In contrast, endometrial PAA did not differ among groups (P > 0.05). Oestradiol-17beta concentrations on Day 21 were higher in S(2) group than in control group (P < 0.01) and S(3) group (P < 0.05). Progesterone concentrations did not differ among groups (P > 0.05). Oestradiol-17beta concentrations could positively affect cervical mucus PAA in control group (P < 0.1), but not in other groups (P > 0.05). These findings suggest that control of estrous cycle by norgestomet administration, in dairy cows, exerts a suppressive effect on plasminogen activators synthesis and/or secretion in the cervical mucus, regardless of the absence or the presence of the CL. On the contrary, endometrial PAA is not affected by norgestomet treatment.
Bargouli
G G
GG
Department of Clinical Studies, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Tsantarliotou
M P
MP
Brozos
C N
CN
Kokolis
N A
NA
Boscos
C M
CM
D000818:Animals; D002417:Cattle / Q000502:physiology*; D002582:Cervix Mucus / Q000378:metabolism*; D003338:Corpus Luteum / Q000502:physiology; D004343:Drug Implants; D004717:Endometrium / Q000378:metabolism*; D030762:Estrous Cycle / Q000502:physiology; D005260:Female; D010960:Plasminogen Activators / Q000187:drug effects* / Q000378:metabolism*; D011282:Pregnenediones / Q000494:pharmacology*; D011897:Random Allocation
D004343:Drug Implants; D011282:Pregnenediones; C100284:norgestomet; D010960:Plasminogen Activators